Literature DB >> 19127022

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice.

Eiki Takimoto1, Norimichi Koitabashi, Steven Hsu, Elizabeth A Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L Gabrielson, Robert Blanton, David P Siderovski, Michael E Mendelsohn, David A Kass.   

Abstract

The heart initially compensates for hypertension-mediated pressure overload by enhancing its contractile force and developing hypertrophy without dilation. Gq protein-coupled receptor pathways become activated and can depress function, leading to cardiac failure. Initial adaptation mechanisms to reduce cardiac damage during such stimulation remain largely unknown. Here we have shown that this initial adaptation requires regulator of G protein signaling 2 (RGS2). Mice lacking RGS2 had a normal basal cardiac phenotype, yet responded rapidly to pressure overload, with increased myocardial Gq signaling, marked cardiac hypertrophy and failure, and early mortality. Swimming exercise, which is not accompanied by Gq activation, induced a normal cardiac response, while Rgs2 deletion in Galphaq-overexpressing hearts exacerbated hypertrophy and dilation. In vascular smooth muscle, RGS2 is activated by cGMP-dependent protein kinase (PKG), suppressing Gq-stimulated vascular contraction. In normal mice, but not Rgs2-/- mice, PKG activation by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardiac hypertrophy, inhibiting Gq-coupled stimuli. Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both genotypes, but PKG plasma membrane translocation was more transient in Rgs2-/- myocytes than in controls and was unaffected by PDE5 inhibition. Thus, RGS2 is required for early myocardial compensation to pressure overload and mediates the initial antihypertrophic and cardioprotective effects of PDE5 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19127022      PMCID: PMC2631292          DOI: 10.1172/JCI35620

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Transgenic Galphaq overexpression induces cardiac contractile failure in mice.

Authors:  D D D'Angelo; Y Sakata; J N Lorenz; G P Boivin; R A Walsh; S B Liggett; G W Dorn
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Regulation of gene expression by cyclic GMP-dependent protein kinase requires nuclear translocation of the kinase: identification of a nuclear localization signal.

Authors:  T Gudi; S M Lohmann; R B Pilz
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Akt1 is required for physiological cardiac growth.

Authors:  Brian DeBosch; Iya Treskov; Traian S Lupu; Carla Weinheimer; Attila Kovacs; Michael Courtois; Anthony J Muslin
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

Review 4.  Negative regulators of cardiac hypertrophy.

Authors:  Stefan E Hardt; Junichi Sadoshima
Journal:  Cardiovasc Res       Date:  2004-08-15       Impact factor: 10.787

5.  Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy.

Authors:  Wei Zhang; Thomas Anger; Jialin Su; Jianming Hao; Xiaomei Xu; Ming Zhu; Agnieszka Gach; Lei Cui; Ronglih Liao; Ulrike Mende
Journal:  J Biol Chem       Date:  2005-12-26       Impact factor: 5.157

6.  Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy.

Authors:  Mitsutaka Yamamoto; Guiping Yang; Chull Hong; Jing Liu; Eric Holle; Xianzhong Yu; Thomas Wagner; Stephen F Vatner; Junichi Sadoshima
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

7.  Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation.

Authors:  Mark S Taylor; Chris Okwuchukwuasanya; Christian K Nickl; Werner Tegge; Joseph E Brayden; Wolfgang R G Dostmann
Journal:  Mol Pharmacol       Date:  2004-05       Impact factor: 4.436

8.  Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II.

Authors:  Yunzeng Zou; Hiroshi Akazawa; Yingjie Qin; Masanori Sano; Hiroyuki Takano; Tohru Minamino; Noriko Makita; Koji Iwanaga; Weidong Zhu; Sumiyo Kudoh; Haruhiro Toko; Koichi Tamura; Minoru Kihara; Toshio Nagai; Akiyoshi Fukamizu; Satoshi Umemura; Taroh Iiri; Toshiro Fujita; Issei Komuro
Journal:  Nat Cell Biol       Date:  2004-05-16       Impact factor: 28.824

9.  Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro.

Authors:  J Sadoshima; Y Xu; H S Slayter; S Izumo
Journal:  Cell       Date:  1993-12-03       Impact factor: 41.582

10.  Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure.

Authors:  K Mary Tang; Guang-rong Wang; Ping Lu; Richard H Karas; Mark Aronovitz; Scott P Heximer; Kevin M Kaltenbronn; Kendall J Blumer; David P Siderovski; Yan Zhu; Michael E Mendelsohn; Mary Tang; Guang Wang
Journal:  Nat Med       Date:  2003-11-09       Impact factor: 53.440

View more
  93 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 2.  A finer tuning of G-protein signaling through regulated control of RGS proteins.

Authors:  Jacob Kach; Nan Sethakorn; Nickolai O Dulin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-27       Impact factor: 4.733

Review 3.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

4.  The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.

Authors:  Sharron H Francis
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

5.  Phosphorylation of TRPC6 channels at Thr69 is required for anti-hypertrophic effects of phosphodiesterase 5 inhibition.

Authors:  Motohiro Nishida; Kenta Watanabe; Yoji Sato; Michio Nakaya; Naoyuki Kitajima; Tomomi Ide; Ryuji Inoue; Hitoshi Kurose
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

Review 6.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 7.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  Prevention of PKG-1α Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation.

Authors:  Taishi Nakamura; Guangshuo Zhu; Mark J Ranek; Kristen Kokkonen-Simon; Manling Zhang; Grace E Kim; Kenichi Tsujita; David A Kass
Journal:  Circ Heart Fail       Date:  2018-03       Impact factor: 8.790

9.  NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth.

Authors:  Irina M Jaba; Zhen W Zhuang; Na Li; Yifeng Jiang; Kathleen A Martin; Albert J Sinusas; Xenophon Papademetris; Michael Simons; William C Sessa; Lawrence H Young; Daniela Tirziu
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

10.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.